αi-mediated TRPC4 activation by polycystin-1 contributes to endothelial function via STAT1 activation

Misun Kwak, Chansik Hong, Jongyun Myeong, Eunice Y. J. Park, Ju-Hong Jeon & Insuk So

Hypertension and aneurysm are frequently associated with autosomal dominant polycystic kidney disease (ADPKD) caused by polycystin-1 (PC1) mutations, which is closely related to endothelial dysfunction. PC1 is an atypical G-protein-coupled receptor that activates G-proteins by self-cleavage; currently, however, the molecular and cellular mechanisms of the associated intracellular signaling and ion channel activation remain poorly elucidated. Here, we report an activation mechanism of a calcium-permeable canonical transient receptor potential 4 (TRPC4) channel by PC1 and its endothelial function. We found that the inhibitory Gαi3 protein selectively bound to the G-protein-binding domain on the C-terminus of PC1. The dissociation of Gαi3 upon cleavage of PC1 increased TRPC4 activity. Calcium influx through TRPC4 activated the transcription factor STAT1 to regulate cell proliferation and death. The down-regulation of PC1/TRPC4/STAT1 disrupted migration of endothelial cell monolayers, leading to an increase in endothelial permeability. These findings contribute to greater understanding of the high risk of aneurysm in patients with ADPKD.

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited diseases. ADPKD is characterized by the progressive expansion, in both kidneys, of multiple fluid-filled cysts, which gradually replace normal renal tissue and ultimately result in end-stage renal failure. In ADPKD-causative genes, the PKD1 gene, which encodes polycystin-1 (PC1) and accounts for 85% of all cases, is involved in the control of epithelial cell population growth, migration, differentiation and apoptosis. In addition, PC1 is required for regulation of the cell cycle and activation of cation-permeable currents by regulation of G-protein signaling. PC1 is a glycoprotein that consists of approximately 4,302 amino acids, weighs approximately 460 kDa and has 11 transmembrane domains, with a huge N-terminal extracellular region including the G protein-coupled receptor (GPCR) proteolytic site (GPS) motif. Previous studies have suggested that PC1 functions as an atypical GPCR, binds heterotrimeric Gαi/o proteins and regulates calcium flux through PC2 (TRPP2) by releasing Gβγ subunits. In addition, N-terminal cleavage of PC1 at the GPS motif promotes the formation of various C-terminal fragments or tails (CTFs or CTTs), which modulate diverse signaling pathways via translocation to the nucleus. In addition, missense mutations in the GPS disrupt the cleavage of PC1 and prevent activation of the JAK-STAT pathway. The dissociation of PC1 from the N-terminal fragment (NTF) or CTF is related to disturbed intracellular Ca2+ homeostasis and cAMP accumulation, leading to abnormal cell proliferation and the growth of multiple cysts. Thus, calcium and cAMP are important regulatory players in the cell biology of PKD.

Transient receptor potential (TRP) channels make up a family of seven cationic channels, which are divided into 7 subfamilies based on amino acid similarity. TRP channels can form functional homo- or hetero-tetrameric channels with intra-subgroups or even with inter-subfamilies. The polycystic type of TRP (TRPP) channel is associated with polycystic kidney disease, which results from abnormal Ca2+ homeostasis and signaling. Newby et al. suggested that the TRPP2/PC1 receptor-ion channel complex plays a critical role in renal physiology. The...
classical TRP (TRPC) is a receptor-operated channel (via G protein-coupling), which is primarily activated in response to PLC activation or inhibitory Gα (Gαi) interactions. By inducing dissociation of heterotrimeric Gαi(3)/βγ proteins by PC1, we hypothesized that PC1 could activate the TRPC4 channel via Gαi(3).

Vascular endothelial cell Ca2+- entry through TRPC4 leads to vascular smooth muscle relaxation in an endothelial acetylcholine-dependent manner, as well as endothelial hyperpermeability via disruption of cell junction complexes or cytoskeletal reorganization. Cerebral aneurysms are more common in ADPKD patients with loss of function or missense mutations in the PC1-encoding PKD1 gene. Accordingly, the functional interaction of TRPC4 with PC1 is essential for Ca2+ regulation in the endothelium, but their pathophysiological mechanisms remain unknown.

In the present study, we overexpressed recombinant TRPC4 and PC1 in HEK cells and analyzed ion channel activity using electrophysiological techniques and Ca2+-dependent signaling using molecular biological methods. Furthermore, we confirmed the functional interaction of TRPC4 with PC1 in HUVECs. Taken together, these findings are consistent with Gαi-dependent TRPC4 activation by the PC1 protein. The Gαi dissociation by GPS cleavage of PC1 activates TRPC4, which in turn elevates Ca2+ levels available for triggering the activation of STAT1 in endothelial cells.

Results
Identification of polycystin-1 (PC1).
Polycystin-1 (PC1) is a large plasma membrane glycoprotein that undergoes several proteolytic cleavages, including autocatalytic cleavage at the G protein-coupled receptor proteolytic site (GPS) (Fig. 1). The cleaved PC1 consists of an N-terminal fragment (NTF) associated with a C-terminal fragment (CTF). At least three other cleavages liberate portions of the cytoplasmic C-terminal tail (CTT) of PC1 (Fig. 1A,B). To determine PC1 expression patterns, we used variously tagged (e.g., GFP, Flag, and HA) constructs at each terminus of PC1 and performed Western blot analysis with several detection antibodies using lysates of HEK293 cells expressing human PKD1 (Fig. 1B). Using an antibody against the PC1 N-terminus (7E12), two bands at >460 kDa, full-length (FL) at 520 kDa and NTF at 440 kDa, were observed in a PC1 construct flag-tagged at the N terminus (PC1-Flag (FL-Flag)) and a PC1 construct GFP-tagged at the C terminus (PC1-GFP (FL-GFP)) (Fig. 1C, Supplementary Fig. 9). With an antibody against the PC1 C-terminus (A-20), FL and CTF (130 kDa) were detected in PC1-Flag, and FL-GFP and CTF-GFP (157 kDa), a cleavage product of hPC1-GFP, were detected in PC1-GFP (Fig. 1C, Supplementary Fig. 9). With an antibody against GFP (GFP), FL-GFP and CTF-GFP were detected in PC1-GFP. With an antibody against Flag (Flag), CTF was detected in CTF-Flag.

Characterization of PC1 as a G protein-coupled receptor (GPCR).
A fundamental feature of PC1 is post-translational modification via cleavage at the juxtamembrane GPS proteolysis site (GPS) motif that is part of the larger GAIN domain. The PC1 C-terminal cytosolic domain also has a G protein activation region, which is defined as a sequence of ≤25 amino acids with the consensus motif BB...BBxB or BB...BBxxB (B = R, K, or H) (Fig. 2A). Signaling pathways of PC1 may be mediated by activating or binding to heterotrimeric G proteins.

Therefore, PC1 may act as an atypical GPCR, which belongs to the GPCR family with GAIN domain.

To identify binding between PC1 and specific Gα subunits, we heterologously expressed CTF of PC1 (PC1(CTF)) and Gα subunits in HEK293 cells and analyzed them via co-immunoprecipitation (Co-IP) and FRET imaging (Fig. 2). The CTF of PC1 has a C-terminal cytoplasmic tail (CTT), including a G protein activation region and a coiled-coil domain. The CTF of PC1 was used because the N-terminal extracellular region does not participate in cleavage signaling. Protein was immunoprecipitated with anti-A-20 and then probed with anti-Gα antibodies. The IP band was observed only for the co-expression of PC1(CTF) with Gαi3, indicating that PC1 specifically interacts with Gαi3 (Fig. 2B, Supplementary Fig. 10). The FRET efficiency between PC1(CTF) and Gαi3 was also measured. When we co-transfected CTF-tagged PC1(CTF) and YFP-tagged Gαi3, the highest FRET efficiency was recorded between PC1(CTF) and Gαi3 (Fig. 2C). Next, the interaction between full-length PC1 (PC1(FL)) and Gαi3 was investigated (Supplementary Fig. 1A). The binding was weaker than for PC1(CTF) (Supplementary Fig. 1C). A GPS site deletion mutant (∆GPS) was also used to evaluate the interaction with Gαi3 (Supplementary Fig. 1B). Other G proteins, e.g., Gαo, Gαq, and Gα13, did not bind with PC1(CTF) (Supplementary Fig. 2A). These results suggest that PC1 is able to bind to specific G protein subunits and likely acts as a GPCR in cells and tissues.

The activation of the TRPC4 channel by PC1 cleavage.
Since PC1 is considered a GPCR, albeit an atypical one, and TRPC4 is can be activated by GPCR, we investigated whether PC1 affects TRPC4 channel currents. The TRPC4 channels expressed in HEK293 cells had lower basal activity. The measurements of TRPC4 activity could be manipulated by altering the extracellular ion composition. To efficiently measure TRPC4 activity, we used 140 mmol/L Cs+ rich solution on the basis of the high permeability of Cs+ ions in TRPC4. The amplitude of TRPC4 currents was 4 ± 1 pA/pF (n = 7) in 140 mmol/L Cs+ rich solution. When TRPC4 was co-expressed with PC1(FL), TRPC4 current was increased by PC1(FL) (41 ± 14 pA/pF, n = 7) under Cs+- rich conditions (Fig. 3A,B). The co-expression of TRPC4 with PC1(CTF) did not increase TRPC4 currents (7 ± 3 pA/pF, n = 3) compared with controls (Fig. 3B). To activate TRPC4, we used intracellular GTPγS, which activates different types of G proteins, through a patch pipette. Intracellular GTPγS administration fully activated TRPC4. GTPγS-induced Ca2+ currents in TRPC4 by PC1(FL) or PC1(CTF) showed no differences compared with controls (Fig. 3C,D). We investigated whether Gαi3 that was dissociated from CTT by cleavage of PC1 affected TRPC4 activity. We observed the interaction of TRPC4 with Gαi3 in both the presence and absence of PC1(FL) using Co-IP. Expression of PC1(FL) significantly increased their physical interaction (Fig. 3E, Supplementary Fig. 11). TRPC4 current was inhibited by a dominant negative form of Gαi3 protein (Gαi3 G202T) in HEK cells transfected with PC1(FL) (Fig. 3F). To determine whether PC1 constitutively activates the TRPC4 channel, we performed Ca2+ measurements and analyzed the relative increase in calcium. PC1(FL)
significantly increased TRPC4β-mediated Ca\(^{2+}\) influx when the external Ca\(^{2+}\) was increased from 0 mmol/L to 2 mmol/L (Fig. 3G,H). The pretreatment of 100 ng/ml PTX partially attenuated the relative increase of Ca\(^{2+}\) in HEK cells co-expressed with PC1 and TRPC4β (Fig. 3I). Finally, we investigated whether PC1 increases TRPC4β currents by regulating channel expression. PC1 did not increase the surface expression of TRPC4β channel. These results suggest that the activation of TRPC4β by PC1 is mediated by G\(_{\alpha}\), leading to increased intracellular Ca\(^{2+}\) levels.
PC1 is constitutively cleaved at His-Leu↓Thr3049 (between Leu3048 and Thr3049) within the GPS domain. The most well-characterized mechanism is the cis-autoproteolysis, a self-catalyzed protein rearrangement that results in cleavage at HX↓(T/S/C) where X indicates all amino acids. Mutants of non-cleavable PC1 were generated by site-specific mutagenesis to confirm cleavage at the GPS domain and to investigate the role of consensus HLT sequences for cleavage (Fig. 4A). Such a mechanism of cis-autoproteolysis requires Thr, Ser, and Cys, which contain nucleophilic side chains (–OH or –SH group) to support cleavage. Substitution of Thr by Ser or Cys did not disrupt the cleavage. In contrast, substitution of Thr by Val, Gly, or Arg and deletion of the GPS domain (ΔGPS) blocked the cleavage. To confirm the correlation between cleavage and pathologic mutations affecting the sequence at or near GPS, two germline mutants (L2993P and Q3016R) were examined. Each of the mutants almost completely inhibited the cleavage (Fig. 4B, Supplementary Fig. 12). Next, we investigated whether the activation of TRPC4β depended on PC1 cleavage at the GPS site. Non-cleavable mutants (L2993P, Q3016R and T3049G/R/V) did not activate TRPC4β channels. In contrast, TRPC4β currents were increased in cells transfected with T3049C or T3049S, where cleavage occurs at the GPS (Fig. 4C). These results suggest that cleavage at the HL↓T of PC1 is required for the activation of TRPC4 channels.

**STAT1 phosphorylation by PC1-mediated activity of TRPC4β.** PC1 has been implicated in a variety of intracellular signaling events, including JAK-STAT signaling. Overexpression of full-length PC1 can activate signal transducer and activator of transcription 1 (STAT1), STAT3 and STAT6, which mediate signaling involved in proliferation, differentiation and death. STATs are phosphorylated and activated by protein tyrosine kinases, including growth factor receptors such as EGFR, and non-receptor tyrosine kinases (e.g., Src and JAK). To confirm whether STAT1 activation by PC1 was independently regulated by Src kinase activity, we transiently transfected HEK 293 cells with dominant-negative Src (Src DN) mutants. The basal level of phosphorylated STAT1 was not detected in HEK cells or changed by Src DN expression. STAT1 was activated by PC1 and wild-type Src (Src WT), and co-expression of PC1 and Src further increased STAT1 activation levels. Activation of STAT1 by PC1 was not affected by Src DN (Fig. 5A,D, Supplementary Fig. 13). These results suggest that cleavage at the HL↓T of PC1 is required for the activation of TRPC4 channels.

PC1 is constitutively cleaved at His-Leu↓Thr3049 (between Leu3048 and Thr3049) within the GPS domain. The most well-characterized mechanism is the cis-autoproteolysis, a self-catalyzed protein rearrangement that results in cleavage at HX↓(T/S/C) where X indicates all amino acids. Mutants of non-cleavable PC1 were generated by site-specific mutagenesis to confirm cleavage at the GPS domain and to investigate the role of consensus HLT sequences for cleavage (Fig. 4A). Such a mechanism of cis-autoproteolysis requires Thr, Ser, and Cys, which contain nucleophilic side chains (–OH or –SH group) to support cleavage. Substitution of Thr by Ser or Cys did not disrupt the cleavage. In contrast, substitution of Thr by Val, Gly, or Arg and deletion of the GPS domain (ΔGPS) blocked the cleavage. To confirm the correlation between cleavage and pathologic mutations affecting the sequence at or near GPS, two germline mutants (L2993P and Q3016R) were examined. Each of the mutants almost completely inhibited the cleavage (Fig. 4B, Supplementary Fig. 12). Next, we investigated whether the activation of TRPC4β depended on PC1 cleavage at the GPS site. Non-cleavable mutants (L2993P, Q3016R and T3049G/R/V) did not activate TRPC4β channels. In contrast, TRPC4β currents were increased in cells transfected with T3049C or T3049S, where cleavage occurs at the GPS (Fig. 4C). These results suggest that cleavage at the HL↓T of PC1 is required for the activation of TRPC4 channels.

**STAT1 phosphorylation by PC1-mediated activity of TRPC4β.** PC1 has been implicated in a variety of intracellular signaling events, including JAK-STAT signaling. Overexpression of full-length PC1 can activate signal transducer and activator of transcription 1 (STAT1), STAT3 and STAT6, which mediate signaling involved in proliferation, differentiation and death. STATs are phosphorylated and activated by protein tyrosine kinases, including growth factor receptors such as EGFR, and non-receptor tyrosine kinases (e.g., Src and JAK). To confirm whether STAT1 activation by PC1 was independently regulated by Src kinase activity, we transiently transfected HEK 293 cells with dominant-negative Src (Src DN) mutants. The basal level of phosphorylated STAT1 was not detected in HEK cells or changed by Src DN expression. STAT1 was activated by PC1 and wild-type Src (Src WT), and co-expression of PC1 and Src further increased STAT1 activation levels. Activation of STAT1 by PC1 was not affected by Src DN (Fig. 5A,D, Supplementary Fig. 13). These results suggest that cleavage at the HL↓T of PC1 is required for the activation of TRPC4 channels.

**Figure 2.** Interaction of PC1(CTF) with Gαi3. (A) Alignment of amino acid sequences of the PC1 C-terminal cytoplasmic tail across many species. The G protein activation region of the PC1 C-terminal tail is conserved across many species (residues 4135-4154 of human PC1). This region is highlighted by the yellow shading. (B) Interactions between PC1(CTF) and Gαi/o subtypes. Gαi/o subtypes and PC1(CTF) were co-expressed in HEK 293 cells. 500μg of proteins from each condition were subjected to immunoprecipitation with anti-A-20 and probed with an antibody against Gαi3 proteins. PC1(CTF) interacts directly with Gαi3 but not with other Gαi/o subtypes. (C) FRET-detectable interactions between PC1(CTF) and Gαi subtypes. Representative FRET images of hPKD1(CTF)-ECFP co-expressed with Gαi1(WT)-, Gαi2(WT)-, and Gαi3(WT)-EYFP compared to empty vector (pEYFP-N1) expression. A bar graph of FRET efficiency between PC1(CTF) and Gαi subtypes.
was inhibited by DAPT, indicating that STAT1 phosphorylation is associated with CTT cleaved from PC1. To investigate the potential role of Ca\(^{2+}\) entry through the TRPC4 channel in increased STAT1 phosphorylation, we observed the effects of removing extracellular calcium ions using Ca\(^{2+}\)-free media. The increased level of STAT1
was significantly attenuated in Ca\(^{2+}\)-free medium compared with normal conditions (Fig. 5C,F, Supplementary Fig. 13). These results suggest that the CTT of PC1 activates TRPC4\(\beta\) via G\(\alpha\)\(i\)3 protein and that calcium influx through TRPC4\(\beta\) is required for the activation of STAT1.

### Effects of the PC1/TRPC4\(\beta\)/STAT1 pathway on endothelial migration.

The TRPC family plays a role in normal and pathophysiological vascular functions\(^{35,36}\). TRPCs are involved in vascular tone (e.g., TRPC4, TRPV1, and TRPV4), regulation of vascular permeability (e.g., TRPC1, TRPC4, TRPC6, and TRPV1), hypoxia-induced vascular remodeling (e.g., TRPC4), angio genesis (e.g., TRPC4 and TRPC6), endothelial cell proliferation, and apoptosis\(^{37}\). TRPC4 plays significant roles in normal and pathophysiological vascular function. PC1 also has an important role in vascular function. PC1 knock-out mice died in mid-gestation with a variety of phenotypes, including a vasculopathy characterized by profound edema\(^{38,39}\). To investigate the relationship between the PC1/TRPC4\(\beta\) pathway and endothelial function, we first investigated the expression of TRPC4 and PC1 in HUVECs using Western blot analysis. Expression of PC1 was detected with anti-7E12 or anti-A-20 antibodies in endothelial cells (Fig. 6A, Supplementary Fig. 14). TRPC4\(\beta\) was predominantly expressed in endothelial cells compared with TRPC4\(\alpha\) isoforms (Fig. 6B, Supplementary Fig. 14). In addition, G\(\alpha\)\(i\)3 was expressed in the given cell lines (Supplementary Fig. 5). These results show that all signaling proteins related to the PC1-G\(\alpha\)\(i\)3-TRPC4\(\beta\) pathway are expressed in HUVECs.

First, we examined the silencing effect of TRPC4\(\beta\) and PC1 on HUVEC migration. In wound-healing assays, endothelial cells treated with vehicle were able to close ~100% of the wound. In contrast, endothelial cells treated with 20\(\mu\)mol/L ML204, a TRPC4 inhibitor, were only able to close ~40% of the wound (Fig. 6E). The migration rate of HUVECs transfected with PKD1 siRNA or TRPC4 siRNA was also significantly decreased (Fig. 6C,D). To identify whether STAT1 affects endothelial migration, STAT1 siRNA was transfected into HUVECs. The migration of STAT1-knocked-down cells was inhibited, as predicted (Fig. 6F). To test siRNA efficiency, PC1, TRPC4 and STAT1 transcript levels were evaluated by Western blot. The tested siRNAs effectively reduced the levels of protein expression (Supplementary Fig. 6). These results suggest that PC1/TRPC4\(\beta\)/STAT1 pathway is expressed in HUVECs.

First, we examined the silencing effect of TRPC4\(\beta\) and PC1 on HUVEC migration. In wound-healing assays, endothelial cells treated with vehicle were able to close ~100% of the wound. In contrast, endothelial cells treated with 20\(\mu\)mol/L ML204, a TRPC4 inhibitor, were only able to close ~40% of the wound (Fig. 6E). The migration rate of HUVECs transfected with PKD1 siRNA or TRPC4 siRNA was also significantly decreased (Fig. 6C,D). To identify whether STAT1 affects endothelial migration, STAT1 siRNA was transfected into HUVECs. The migration of STAT1-knocked-down cells was inhibited, as predicted (Fig. 6F). To test siRNA efficiency, PC1, TRPC4 and STAT1 transcript levels were evaluated by Western blot. The tested siRNAs effectively reduced the levels of protein expression (Supplementary Fig. 6). These results suggest that PC1/TRPC4\(\beta\)/STAT1 pathway plays an important role in endothelial migration.

To evaluate the functional activity of TRPC4, we measured the channel currents and the intracellular Ca\(^{2+}\) levels by knock-down of TRPC4. In HUVECs transfected with siControl, basal TRPC4 activity showed constitutively active current, which was induced by CaCl. Englerin A (EA), a TRPC4 agonist, slightly increased the inward current of TRPC4. Both basal and EA-evoked currents showed typical double-rectifying current-voltage relationships known to be features of the TRPC4 channel (Fig. 6G). By knock-down of TRPC4, the TRPC4-like current was completely reduced. EA-induced Ca\(^{2+}\) influx was also reduced by knock-down of TRPC4 (Fig. 6G, Supplementary Fig. 7A).

### Effects of the PC1/TRPC4\(\beta\)/STAT1 pathway on adherens junctions.

To determine whether PC1 or TRPC4\(\beta\) affects vascular permeability, we investigated the distribution of an endothelial-specific cadherin,
VE-cadherin, and leakage of Evans blue dye in HUVECs. We evaluated the endothelial permeability using Evans blue dye. Upon siTRPC4 or ML204 treatment with or without siPKD1, the permeability of the endothelial cell monolayers to Evans blue dye was significantly increased (Fig. 7A,B). Next, the junction protein VE-cadherin was visualized via immunofluorescence staining. Treatment with siPKD1, ML204 or siSTAT1 decreased junction-localized VE-cadherin levels (Fig. 7C). Subsequently, the expression of VE-cadherin was assessed by Western blot analysis. There was no significant difference in the protein level of VE-cadherin (Supplementary Fig. 8). These data show that PC1 knock-down, ML204 or siSTAT1 treatment on endothelial cells induced VE-cadherin internalization. These results suggest that PC1-mediated TRPC4β activation plays an important role in the stability of endothelial junctions and permeability.

Discussion
In the present study, we found that PC1-mediated TRPC4β activity plays a key role in endothelial migration and permeability. We have shown that TRPC4β can be activated by PC1, although its mechanism is not clear. Several lines of evidence suggest that PC1 functions as a G protein-coupled receptor. First, the C-terminal tail of PC1 contains a G protein-binding region. This region is conserved across many species. In our hands, PC1 coimmuno-precipitated with Gαi3, indicating that PC1 specifically interacts with the Gαi3 protein. FRET efficiency between PC1 and Gαi3 also increased compared with other Gαi isoforms. Second, PC1 is cleaved at the GPS, which is in an immediate location of the first transmembrane domain, and this cleavage results in G protein-mediated signaling cascades. The GPS motif was first identified as a neuronal GPCR, CIRL/latrophilin40, and has recently been recognized as a part of the larger GPCR autoproteolysis-inducing (GAIN) domain, which is also found in PC1. Interestingly, the cleaved PC1 N-terminal fragment remains non-covalently attached to the membrane-bound C-terminal fragment29. Such a heterodimeric PC1 is required to transduce the signal through G proteins and plays an important role in biological functions. In contrast, it has been reported that deletion of the NTF results in constitutive activation of several aGPCRs41, suggesting that NTF association might normally prevent constitutive activation. Interestingly, all of the disease-associated missense mutations located in the GAIN domain and the adjacent REJ module of PC1 analyzed to date impair or disrupt cleavage. Defective GPS cleavage of PC1 has been found in a subset of ADPKD patients with aneurysmal rupture42. We generated non-cleavable mutants of PC1 and identified the loss of functional properties of PC1 in activating the TRPC4β channel through the Gαi protein.

In a previous report, we showed that Gαi proteins played an essential and novel role in the activation of TRPC4β. In our hands, PC1 activated the TRPC4β channel through the Gαi protein. First, PC1(FL) but not PC1(CTF) activated TRPC4β. PC1(CTF) alone did not activate TRPC4β because NTF is required for G
protein-mediated signaling through the C-terminal tail of PC1. Second, non-cleavable mutants of PC1 did not activate TRPC4\(\beta\) current when cleavage of PC1 N-terminus and C-terminus was blocked by missense mutations at the GPS domain. Third, when intracellular Ca\(^{2+}\) levels were measured using Fura-2, PC1(FL) increased Ca\(^{2+}\) influx through the TRPC4\(\beta\) channel. Fourth, intracellular 0.2 mmol/L GTP\(\gamma\)S-induced TRPC4\(\beta\) activation was

Figure 6. Effects of PC1 and TRPC4\(\beta\) on HUVECs. (A) Expression of PC1 in HUVECs. HEK293 cells with or without transient transfection of hPC1(FL)-flag were immunoblotted with an anti-PC1. Endogenous PC1 in HEK 293 cells and HUVECs was detected by an anti-PC1 antibody (7E12) (left panel). HEK 293 cells with or without transient transfection of hPC1(FL)-flag and HA-hPC1(CTF)-flag were immunoblotted with an anti-PC1 antibody (A-20) (right panel). Cleavage of endogenous PC1 in HUVECs; NFT (green arrow) and CTF (blue arrow) were detected. (B) Expression of TRPC4 in HUVECs. HEK293 cells with or without transient transfection of TRPC4\(\alpha\) or TRPC4\(\beta\) were immunoblotted with an anti-TRPC4 antibody. Endogenous TRPC4\(\beta\) in HUVECs was detected by an anti-TRPC4 antibody. (C) Effects of PKD1 gene silencing on the migration of HUVECs. Wound healing assays were performed on HUVECs with siPKD1 transfection. (D) Effects of TRPC4 gene silencing on the migration of HUVECs. Wound healing assays were performed on HUVECs with siTRPC4 transfection. (E) Effects of ML204 treatment on the migration of HUVECs. Wound healing assays were performed on HUVECs in the absence or presence of the TRPC4 blocker ML204 (20 \(\mu\)mol/L). (F) Effects of STAT1 gene silencing on the migration of HUVECs. Wound healing assays were performed on HUVECs with siSTAT1 transfection. Bar graphs represent quantitative data for the cell migration assays. The area of the wound was measured at the two indicated time points in every group, and the % reduction of the initial scratch area was compared. Yellow indicates the boundary lines of the scratch. Cell migration was assessed by recovery of the scratch. (G) TRPC4 current activity with knock-down of TRPC4 in HUVECs. The I-V relationship is shown before (black) and after (red) Englerin A (EA) treatment. **p < 0.01, *p < 0.05 and n.s. not significant.
Figure 7. Effects of PC1 and TRPC4β on cell–cell junctions. (A) HUVECs were cultured in confluent monolayers on transwell membranes, and treated with siPKD1 and/or siTRPC4. (B) HUVECs were cultured in confluent monolayers on transwell membranes, and treated with siPKD1 and/or ML204. The permeability of the monolayers to Evans blue dye was measured by collecting media from the lower wells and measuring the absorbance at 570 nm. The down-regulation of PC1 and TRPC4 activity increased the permeability. (C) Localization of VE-cadherin in HUVECs treated with siPKD1, ML204 or siSTAT1. Images show a HUVEC monolayer immunolabeled for VE-cadherin (green, upper panel) and nuclei (blue, center panel), as well as the merged images (lower panel). Inhibition of PC1-mediated TRPC4β signaling disrupted the formation of cell–cell junctions. Line intensity scanning was analyzed using MetaMorph software. Statistical significance is denoted by an asterisk (**p < 0.01).
not significantly different in the presence or absence of PC1. Fifth, activation of TRPC4β by PC1(FL) was inhibited by expression of a dominant-negative Goi3 variant. Therefore, these results demonstrate unambiguously that TRPC4β is activated by an atypical Goi3-coupled-receptor, PC1.

Next, we identified intracellular signaling cascades through a rise in cytosolic Ca2+ due to PC1/Goi3/TRPC4β. Many studies have reported that disturbances in the balance between cell proliferation and apoptosis cause ADPKD. Abnormal proliferation in tubular epithelial cells plays a crucial role in cyst development and/or growth in PKD43. The kidneys from patients with ADPKD demonstrate high levels of apoptosis, as well as cellular proliferation44. Intracranial aneurysm is also believed to develop as a result of disruption of the balance between cell proliferation and apoptosis45. Indeed, proliferation and apoptosis must be tightly regulated. Among many regulatory factors of proliferation and apoptosis, we observed activation of STAT1 by PC1/Goi3/TRPC4β. STAT1 is predominantly phosphorylated by activation of PC1-mediated TRPC4β. The Ca2+ influx can also lead to phosphorylation of STAT1 on tyrosine residues.

PC1, which is localized to the primary cilium, functions as a flow-sensitive mechanosensor46. Cleavage of the PC1 protein is a response to various stimuli, such as extracellular fluid flow47. The products of these cleavages perform important physiological functions. Nevertheless, it is still unclear how and where PC1 is cleaved. According to previously reported data, there are cleavage-inducible factors, such as mechanical stimuli48, polycystin-2 (PC2)49, and γ-secretase50. Thus, perfusion flow in calcium imaging and patch clamp experiments may generate mechanosensory stimulation. In our hands, the GPS domain was used to induce autoproteolysis of PC1 into NTF and CTF, whereas the CTT of PC1 was released by γ-secretase-mediated cleavage. The increased levels of STAT1 phosphorylation via PC1-mediated TRPC4β activity were inhibited by treatment with the γ-secretase inhibitor DAPT (Supplementary Fig. 4). Thus, CTT of PC1 activated TRPC4β via the Goi3 protein, and extracellular calcium through TRPC4β was required for the activation of STAT1.

Endothelial dysfunction is a hallmark of aneurysm. Aneurysm is one of the most common manifestations in ADPKD. The dysregulation of TRPC4 results in vascular endothelial dysfunction. A role of TRPC4 in vascular endothelial dysfunction was previously reported that acetylcholine-induced vasorelaxation occurred due to acetylcholine-dependent NO production in aortic endothelial cells, which was largely reduced in TRPC4 knock-out mice49. Reduced calcium entry in TRPC4-deficient lung endothelial cells was also associated with reduced thrombin-induced formation of actin stress fibers, reduced endothelial cell retraction, and reduced microvascular endothelial permeability evoked by a PAR-1 agonist peptide in isolated lungs50. A missense SNP (TRPC4-1957V) in the TRPC4 human gene was further found to be associated with a reduced risk of myocardial infarction. The proposed mechanism underlying protection involved improved endothelial function51. In addition, a TRPC4-mediated Ca2+ signaling pathway evoked by EGF was specifically identified in sub-confluent, proliferating clusters of human microvascular endothelial cells. The abundance of TRPC4 in the plasma membrane and its contribution to Ca2+ entry depend on the proliferation state, and its activity is regulated by cell–cell contact formation in a β-catenin-dependent manner52. In our hands, inhibition of PC1-mediated TRPC4β activity induced endothelial dysfunction, as demonstrated by the reduction of endothelial migration (Fig. 6C–E) and cell–cell junctions (Fig. 7C) by down-regulation of PC1 or TRPC4. Although histamine and thrombin could increase the permeability of HUVECs by a robust Ca2+ release and Ca2+ entry (Supplementary Fig. 7) via receptor-operated and store-operated channel (SOC), sustained Ca2+ influx through TRPC4, which is constitutively activated by PC1, may play a role in refilling the ER Ca2+ stores, which require further investigation. Furthermore, Ca2+-dependent STAT1 participates in other signaling pathways associated with endothelial function in strengthening tight junctions. Thus, knock-down of PKD1, TRPC4 or STAT1 increases endothelial permeability. Based on these findings, we propose the activation of PC1-mediated TRPC4β in endothelial cells as a tentative molecular target for cerebral aneurysms associated with ADPKD.

In conclusion, the main findings of this study are as follows (Fig. 8): (1) PC1(FL) but not PC1(CTF) activates TRPC4β via Goi3. (2) PC1 and TRPC4β increase Ca2+-dependent STAT1 activation. (3) The down-regulation of PC1 and TRPC4β activity reduces endothelial cell migration. (4) Knock-down of STAT1 reduces endothelial cell migration. (5) Inhibition of PC1-mediated TRPC4β signaling increases endothelial cell permeability by disruption of cell–cell junctions. Thus, mutations of PKD1 contribute to endothelial dysfunction via decreased migration and increased endothelial permeability.

Materials and Methods

Cell culture, transient transfection, and chemicals. Human embryonic kidney (HEK)-293 cells (American Type Culture Collection, USA) were maintained in Dulbecco’s modified Eagle’s medium (HyClone, USA) supplemented with 10% fetal bovine serum (FBS), 100 μg/ml penicillin, and 100 μg/ml streptomycin according to the supplier’s recommendations. Human umbilical vein endothelial cells (HUVECs) were cultured in M199 medium (Welgene, South Korea) containing 20% FBS, 3 ng/ml human FGF-basic (Peprotech, USA), and antibiotics. Prior to transient transfection, cells were seeded in 6- or 12-well plates. The following day, 0.5–2 μg well TRPC4β and PKD1 cDNA was transfected into cells using the transfection reagent FuGENE 6 (Roche Molecular Biochemicals, USA) for electrophysiological experiments, according to the manufacturer’s protocol. For molecular biology experiments, Lipofectamine 2000 (Invitrogen, USA) was used as the transfection reagent. All experiments were performed 20–30 hours after transfection. For gene silencing, siRNA was transfected using the transfection reagent RNAi Max (Invitrogen, USA) according to the manufacturer’s instructions. Control siRNA (Cat. SN-1003), human PKD1 siRNA (Cat. 1117253) and human TRPC4 (Cat. 1156755) were purchased from Bioneer (South Korea). Human STAT1 (Cat. sc-4123) was purchased from Santa Cruz (USA). PTX and Englerin A was purchased from Sigma Aldrich (USA).

Plasmids. Human PKD1(FL) in pGFP-N1 and human PKD1(FL)-Flag in pCI-neo plasmids were kindly provided by Eric Honoré and Gregory Germino, respectively. HA-human PKD1(CTF)-Flag in pCI and EGFP-human
PKD1(FL) in pCI were kindly provided by Feng Qian (Johns Hopkins University). Human PKD1(FL) was sub-cloned into the pECFP-N1 and pEYFP-N1 vectors.

**Western blotting, Co-IP, and Surface biotinylation.** Cells were plated in 6-well dishes. Lysates were prepared in lysis buffer (0.5% Triton X-100, 150 mmol/L NaCl, 50 mmol/L HEPES, 2 mmol/L MgCl₂, 2 mmol/L EDTA, pH 7.4) via passage 10–15 times through a 26-gauge needle after sonication. After lysates were centrifuged at 13,000 × g for 10 minutes at 4 °C, the protein concentration in the supernatants was determined. The extracted proteins in sample buffer were loaded onto 5, 8, or 10% Tris-glycine sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels. The proteins were transferred onto a PVDF membrane. For details concerning the antibodies, please see the supplementary materials.

In the Co-IP experiments for detection of PC1-Ga subtypes, 500 μL of cell lysates (500–1000 μg) were incubated with 1 μg of anti-PKD1 (A-20) or anti-Ga antibodies and 30 μL of protein G-agarose beads at 4 °C overnight with gentle rotation. After the beads were washed three times with wash buffer (0.1% Triton X-100), the precipitates were then eluted with 30 μL of 2 × Laemmli buffer and subjected to Western blot analysis.

For surface biotinylation, cells were first washed with PBS and incubated in 0.5 mg/mL sulfo-NHS-LC-biotin (Pierce, USA) in PBS for 30 minutes on ice. The biotin was quenched by 100 mmol/L glycine in PBS. The cells were then processed as described above for cell extraction. Forty microliters of 1:1 slurry of immobilized avidin beads (Pierce, USA) was added to 300 μL of cell lysates (500 μg protein). After incubation for 1 hour at room temperature, the beads were washed three times with 0.5% Triton X-100 in PBS, and proteins were extracted in sample buffer. The collected proteins were analyzed by Western blot.

**Electrophysiology.** The transfected cells were trypsinized and transferred to a recording chamber, which was equipped for the application of a number of solutions. Whole-cell currents were recorded using an Axopatch 200B amplifier (Axon Instruments, USA) and Digidata 1440 A Interface (Axon Instruments), and analyzed using a personal computer equipped with pClamp 10.2 software (Axon Instruments) and Origin software (Microcal origin v.8.0, USA). Patch pipettes were made from borosilicate glass and had resistances of 2–4 MΩ when filled with standard intracellular solutions. For whole cell experiments, we used an external bath medium (normal Tyrode solution) of the following composition (in mmol/L): 135 NaCl, 5 KCl, 2 CaCl₂, 1 MgCl₂, 10 glucose, and 10 N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) with the pH adjusted to 7.4 using NaOH. Cs⁺-rich external solution was made by replacing NaCl and KCl with equimolar CsCl. The standard pipette solution contained the following (in mmol/L): 140 CsCl, 10 HEPES, 0.2 Tris-GTP, 0.5 EGTA, and 3 Mg-ATP with the pH adjusted to 7.3 using CsOH. Intracellular 50 mmol/L, 200 mmol/L, or 5 μmol/L free Ca²⁺ pipette solutions were chosen on the basis of previous studies of TRPC5. Voltage ramp pulses were applied at −60 mV with a holding potential from +100 to −100 mV for 500 ms. A salt-agar bridge was used to connect the ground Ag-AgCl wire to the bath solution for the experiments that used reducing agents. All current traces are the selected values at −60 mV or +80 mV of the ramp pulses. The inward current amplitudes at −60 mV are summarized for all bar graphs. The current recording was performed as previously described.

**Fluorescence Resonance Energy Transfer (FRET) measurements.** Three FRET images (cube settings for CFP, YFP, and Raw FRET) were obtained from a pE-1 Main Unit to 3 FRET cubes (excitation, dichroic mirror, filter) via a fixed collimator. The excitation LED and the filter were sequentially rotated, and the rotation period for each filter cube was ~0.5 s. All of the images were obtained within 1.5 seconds. Each image was captured on a cooled 10 MHz (14 bit) CCD camera (ANDOR technology, USA) with 100 ms of exposure time with 2 × 2 binning (645 × 519 pixels). Using IX70, an Olympus microscope equipped with a 60 × oil objective, the three-cube FRET efficiency was analyzed using MetaMorph 7.6 software (Molecular Devices, USA). For details of FRET ratio and FRET efficiency computation, please see the supplementary materials.

**Intracellular Ca²⁺ measurements with Fura-2.** The ratiometric measurement of [Ca²⁺]i was performed using Fura-2-AM (molecular probe, USA). The cells were seeded in 24-well dishes and loaded with 5 μmol/L of
Fura-2-AM for 30 minutes at 37°C. The Fura-2 fluorescence was measured at 510 nm emission with 340/380 nm dual excitation using a DG-4 illuminator. The experiments were performed in a normal solution containing 145 mM NaCl, 3.6 mM KCl, 10 mM HEPES, 1.3 mM CaCl₂, 1 mM MgCl₂, and 5 mM glucose with pH adjusted to 7.4 using NaOH.

**Wound-healing assay.** HUVECs transfected with PKD1, TRPC4 or STAT1 siRNA were seeded in 6 well culture plates and incubated with ML204, a selective TRPC4 channel inhibitor. Cells were grown as high-density monolayers, scratched with a 200 μL pipette tip, and allowed to migrate for the indicated times after three washes to remove detached cells. Migration was recorded using a Nikon ECLIPSE TS100 microscope equipped with a Lumenera’s INFINITY-1-3 digital camera. The area covered by the monolayer was measured using ImageJ (National Institutes of Health, USA). All migration assays are representative of at least three independent experiments.

**In vitro endothelial permeability assay.** To measure permeability changes of endothelial cells in vitro, HUVECs were cultured to confluence on cell culture inserts (3.0 μm, BD Biosciences) placed in a 12-well plate. 5 × 10⁴ HUVECs were seeded on each cell culture insert. In control samples, 500 μL of Evans blue dye (0.67 mg/mL) was added to the upper compartment to demonstrate that the endothelial layers were impermeable to this dye. Experimental wells were treated with siPKD1, siTRPC4 or ML204 for 48 hours, and 500 μL dye was added to the upper compartments. The liquid was collected from the lower wells after 10 minutes and measured by spectrophotometric absorbance at 570 nm.

**Immunofluorescence microscopy.** HUVECs were treated with siPKD1, siML204 or siSTAT1 for 48 hours. The cells were fixed with 4% paraformaldehyde for 15 minutes. After washing in PBS, cells were incubated with an anti-VE-cadherin antibody at 4°C overnight. VE-cadherin was localized using Alexa Fluor 488 (Invitrogen, USA). Nuclei were stained with Hoechst 33342 (Invitrogen, USA). The cells were examined using a fluorescence microscope, and images were analyzed using Metamorph software (Molecular Devices, USA).

**Statistics.** The results are presented as the means ± s.e.m. They were compared using Student’s t-tests between two groups, or ANOVA followed by post-hoc tests among three or more groups. p < 0.05 was considered statistically significant. The number of cells for electrical recordings is provided as an n value in the bar graphs.

**Data availability.** The data generated during the current study are available from the corresponding author upon reasonable request.

**References**

1. Torres, V. E., Harris, P. C. & Pison, Y. Autosomal dominant polycystic kidney disease. *Lancet* **369**, 1287–301 (2007).
2. Kim, H., Bae, Y., Jeong, W., Ahn, C. & Kang, S. Depletion of PKD1 by an antisense oligodeoxynucleotide induces premature G1/S phase transition. *Eur. J. Hum. Genet.* **12**, 433–40 (2004).
3. Li, X. et al. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. *Nat. Cell Biol.* **7**, 1202–12 (2005).
4. Manzati, E. et al. The cytoplasmic C-terminus of polycystin-1 increases cell proliferation in kidney epithelial cells through serum-activated and Ca(2+)–dependent pathway(s). *Exp. Cell Res.* **304**, 391–406 (2005).
5. Nickel, C. et al. The polycystin-1 C-terminal fragment triggers branching morphogenesis and migration of tubular kidney epithelial cells. *J. Clin. Invest.* **109**, 481–9 (2007).
6. Polgar, K. et al. Disruption of polycystin-1 function interferes with branching morphogenesis of the ureteric bud in developing mouse kidneys. *Dev. Biol.* **286**, 16–30 (2005).
7. Aguiari, G. et al. K562 erythroid and HL60 macrophage differentiation downregulates polycystin, a large membrane-associated protein. *Exp. Cell Res.* **244**, 259–67 (1998).
8. Boca, M. et al. Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. *J. Am. Soc. Nephrol.* **17**, 657–67 (2006).
9. Bhunia, A. K. et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. *Cell* **109**, 157–68 (2002).
10. Vandorpe, D. H. et al. The cytoplasmic C-terminal fragment of polycystin-1 regulates a Ca2+-permeable cation channel. *J. Biol. Chem.* **276**, 4093–101 (2001).
11. Babich, V. et al. The N-terminal extracellular domain is required for polycystin-1-dependent channel activity. *J. Biol. Chem.* **279**, 25582–9 (2004).
12. Pelucchi, R. et al. Nonspecific cation current associated with native polycystin-2 in HEK-293 cells. *J. Am. Soc. Nephrol.* **17**, 388–97 (2006).
13. Parnell, S. C. et al. The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimetric G-proteins in vitro. *Biochem. Biophys. Res. Commun.* **251**, 625–31 (1998).
14. Delmas, P. et al. Constitutive activation of G-proteins by polycystin-1 is antagonized by polycystin-2. *J. Biol. Chem.* **277**, 11276–83 (2002).
15. Merrick, D. et al. Polycystin-1 cleavage and the regulation of transcriptional pathways. *Pediatr. Nephrol.* **29**, 505–11 (2014).
16. Weimbs, T., Olsan, E. E. & Talbot, J. J. Regulation of STATs by polycystin-1 and their role in polycystic kidney disease. *JAKSTAT2*, e23650 (2013).
17. Yamaguchi, T., Hempson, S. J., Reif, G. A., Hedge, A. M. & Wallace, D. P. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. *J. Am. Soc. Nephrol.* **17**, 178–87 (2006).
18. Nilius, B., Owssianik, G., Voets, T. & Peters, J. A. Transient receptor potential cation channels in disease. *Physiol. Rev.* **87**, 165–217 (2007).
19. Hoffherr, A. & Köttgen, M. TRPP channels and polycystins. *Adv. Exp. Med. Biol.* **704**, 287–313 (2011).
20. Newby, L. J. et al. Identification, characterization, and localization of a novel kidney polycystin-1–polycystin-2 complex. *J. Biol. Chem.* **277**, 20763–73 (2002).
21. Schaefer, M. et al. Receptor-mediated regulation of the nonselective cation channels TRPC4 and TRPC5. *J. Biol. Chem.* **275**, 17517–26 (2000).
22. Jeon, J. P. et al. Selective G0i subunits as novel direct activators of transient receptor potential canonical (TRPC4) and TRPC5 channels. *J. Biol. Chem.* **287**, 17029–39 (2012).
23. Graziani, A. et al. Cell-cell contact formation governs Ca2+ signaling by TRPC4 in the vascular endothelium: evidence for a regulatory TRPC4 beta-catenin interaction. *J Biol Chem* **285**, 4213–23 (2010).

24. Mariani, L., Bianchetti, M. G., Schroth, G. & Seiler, R. W. Cerebral aneurysms in patients with autosomal dominant polycystic kidney disease—to screen, to clip, to coil! *Nephrol Dial Transplant* **14**, 2319–22 (1999).

25. Xu, H. W., Yu, S. Q., Mei, C. L. & Li, M. H. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. *Stroke* **42**, 204–6 (2011).

26. Pirson, Y., Chauveau, D. & Torres, V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* **13**, 269–76 (2002).

27. Trudel, M., Yao, Q. & Qian, F. The Role of G-Protein-Coupled Receptor Proteolysis Site Cleavage of Polycystin-1 in Renal Physiology and Polycystic Kidney Disease. *Cells* **5** (2016).

28. Qian, F. & et al. Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. *Proc Natl Acad Sci USA* **9**, 16981–6 (2002).

29. Wei, W., Hackmann, K., Xu, H., Germino, G. & Qian, F. Characterization of cis-autoproteolysis of polycystin-1, the product of human polycystic kidney disease 1 gene. *J Biol Chem* **282**, 21729–37 (2007).

30. Xu, Q., Buckley, D., Guan, C. & Guo, H. C. Structural insights into the mechanism of intramolecular proteolysis. *Cell* **98**, 651–61 (1999).

31. Low, S. H. et al. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. *Dev Cell* **10**, 57–69 (2006).

32. Talbot, J. J. et al. Polycystin-1 regulates STAT activity by a dual mechanism. *Proc Natl Acad Sci USA* **108**, 7985–90 (2011).

33. Levy, D. E. & Darnell, J. E. Jr. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol* **3**, 651–62 (2002).

34. Merrick, D. et al. The Role of G-Protein-Coupled Receptor Proteolysis Site Cleavage of Polycystin-1 in Renal Physiology and Polycystic Kidney Disease. *Cells* **5** (2016).

35. Mariani, L., Bianchetti, M. G., Schroth, G. & Seiler, R. W. Cerebral aneurysms in patients with autosomal dominant polycystic kidney disease–to screen, to clip, to coil? *Nephrol Dial Transplant* **14**, 2319–22 (1999).

36. Levy, D. E. & Darnell, J. E. Jr. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol* **3**, 651–62 (2002).

37. Merrick, D. et al. The γ-secretase cleavage product of polycystin-1 regulates TCF and CHOP-mediated transcriptional activation through a p300-dependent mechanism. *Dev Cell* **22**, 197–210 (2012).

38. Earley, S. & Brayden, J. E. Transient receptor potential channels and vascular function. *Clin Sci (Lond)* **119**, 19–36 (2010).

39. Inoue, R., Hui, L. & Honda, A. Pathophysiological implications of transient receptor potential channels in vascular function. *Curr Opin Nephrol Hypertens* **17**, 193–8 (2008).

40. Yoo, X. & Garland, C. J. Recent developments in vascular endothelial cell transient receptor potential channels. *Circ Res* **97**, 853–63 (2005).

41. Boulter, C. et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. *Proc Natl Acad Sci USA* **98**, 12174–9 (2001).

42. Kim, K., Drummond, I., Ilbraghimov-Beskorovainy, O., Klinger, K. & Arnaout, M. A. Polycystin 1 is required for the structural integrity of blood vessels. *Proc Natl Acad Sci USA* **97**, 1731–6 (2000).

43. Krainanoperov, V. G. et al. alpha-Latrotoxin stimulates exocytosis by the interaction with a neuronal G-protein-coupled receptor. *Neuron* **18**, 925–37 (1997).

44. Paavola, K. J., Stephenson, J. R., Ritter, S. L., Alter, S. P. & Hall, R. A. The N terminus of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. *J Biol Chem* **286**, 28914–21 (2001).

45. Rossetti, S. et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. *Lancet* **361**, 2196–201 (2003).

46. Murcia, N. S., Sweeney, W. E. Jr. & Avner, E. D. New insights into the molecular pathophysiology of polycystic kidney disease. *Kidney Int* **55**, 1187–97 (1999).

47. Lanoix, J., D’Agati, V., Szabo, V., & Trudel, M. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). *Oncogene* **13**, 1153–60 (1996).

48. Chalouhi, N., Hoh, B. L. & Hasan, D. Review of cerebral aneurysm formation, growth, and rupture. *Stroke* **44**, 3613–22 (2013).

49. Nauli, S. M. et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. *Nat Genet* **33**, 129–37 (2003).

50. Chauvet, V. et al. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. *J Clin Invest* **114**(10), 1433–1443 (2004).

51. Chaplin, H. C., Rajendran, V. & Caplan, M. J. Polycystin-1 surface localization is stimulated by polycystin-2 and cleavage at the G protein-coupled receptor proteolytic site. *Mol Biol Cell* **21**(24), 4338–48 (2010).

52. Freichel, M. et al. Lack of an endothelial store-operated Ca2+ current impairs agonist-dependent vasorelaxation in TRPC4−/− mice. *Nat Cell Biol* **3**, 121–7 (2001).

53. Tiruppathi, C. et al. Impairment of store-operated Ca2+ entry in TRPC4−/− mice interferes with increase in lung microvascular permeability. *Circ Res* **91**, 70–6 (2002).

54. Jung, C. et al. A gain-of-function SNP in TRPC4 cation channel protects against myocardial infarction. *Cardiovasc Res* **91**, 465–71 (2011).

55. Hong, C. et al. Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntington’s disease. *Brain* **138**, 3030–47 (2015).

Acknowledgements

This study was supported by grants from the National Research Foundation of Korea, which is funded by the Ministry of Science, Information and Communication Technology (ICT), and Future Planning (MSIP) of the Korean government (grant number: 2015R1A2A1A05001756), the Seoul National University Hospital Research Fund (03-2014-0020) to I.S., and the Ministry of Education of the Korean government (grant number: 2015R1A6A3A04058395) to C. H. Both M.K. and J.M. were supported by the BK21 plus program from the MSIP.

Author Contributions

M. Kwak and C. Hong designed and performed the experiments, analyzed data and wrote the paper with I. So; J. Myeong performed FRET experiments; M. Kwak generated all PC1 mutant constructs; J. Jeon provided technical support; E. Park contributed to calcium measurements and discussion; M. Kwak and I. So discussed the results and their implications and commented on the manuscript at almost all stages.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-21873-1.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
